This is a routine clinical case presentation with no immediate financial or regulatory catalyst. Monitor for future clinical trial results or commercial adoption updates that could drive revenue. The stock's micro-cap status ($3M market cap) means any positive news could have outsized moves, but this filing alone lacks materiality.
Price Chart
Executive Summary
Nuwellis highlighted a pediatric case study presented at ISHLT 2026 showing the use of its Aquadex SmartFlow ultrafiltration therapy in a child with chemotherapy-induced dilated cardiomyopathy and recurrent fluid overload. The presentation supports the therapy's growing evidence base but does not provide new financial data, regulatory approvals, or commercial milestones.
Key Facts
- Case study presented at ISHLT 2026 (April 22–25) by University of Iowa Stead Family Children's Hospital.
- Poster titled 'Therapeutic Ultrafiltration to Treat Symptomatic Pediatric Heart Failure' using Aquadex SmartFlow.
- Patient had chemotherapy-induced dilated cardiomyopathy and recurrent fluid overload unresponsive to diuretics.
- Aquadex is indicated for continuous ultrafiltration in pediatric patients ≥20 kg with fluid overload.
- No new financial data, revenue, EPS, guidance, or regulatory decisions were disclosed.
Financial Impact
No financial impact disclosed; the case study is a clinical presentation, not a revenue-generating event.
Risk Factors
- No new revenue or commercial traction disclosed; the company remains pre-revenue or low-revenue.
- Forward-looking statements highlight risks of insufficient funding and commercialization challenges.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3283761 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $0.3221 | awaiting T+20 | — | $3.07 (+851.69%) |
Sep 18, 2026 5w ago | SC 13G/A | $0.8700 $0.5600 | ▼ −35.63% | ▼ −34.72% | $3.07 (+252.34%) |
Sep 17, 2026 5w ago | Press Release | $1.09 $0.5532 | ▲ +49.25% | ▲ +50.45% | $3.07 (−181.23%) |
Aug 27, 2026 8w ago | EFFECT | $0.9900 $0.7915 | ▲ +20.05% | ▲ +19.95% | $3.07 (−209.64%) |
Aug 25, 2026 9w ago | 8-K | $1.01 $0.8700 | ▼ −13.86% | ▼ −15.06% | $3.07 (+203.50%) |
Aug 13, 2026 10w ago | Press Release | $1.30 $0.7740 | ▲ +40.46% | ▲ +38.71% | $3.07 (−135.80%) |
Aug 3, 2026 12w ago | 424B5 | $14.49 $7.13 | ▲ +50.78% | ▲ +52.01% | $3.07 (+78.84%) |
Jul 31, 2026 12w ago | Press Release | $1.74 $0.8889 | ▲ +48.91% | ▲ +51.90% | $3.07 (−76.17%) |
Jun 16, 2026 19w ago | Press Release | $0.1350 $0.0840 | ▼ −37.78% | ▼ −37.83% | $3.07 (+2170.67%) |
Jun 10, 2026 19w ago | 8-K | $0.1520 $0.0869 | ▲ +42.86% | ▲ +46.93% | $3.07 (−1916.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers